Fu Hong Han Lin (02696): New indications of Hans Xiang® and Futunin® were included in the National Medical Insurance Drug List

Zhitongcaijing · 1d ago

Zhitong Finance App News, Fu Hong Han Lin (02696) announced that recently, Hans Xiang® (slulizumab injection) was included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2026)” for the first time. The included indications include all indications approved for marketing in China (excluding Hong Kong, Macao and Taiwan regions of China, same below). In addition, Futunine® (vorvicil citrate capsules) added its second indication to the national medical insurance drug catalogue. The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2027.

The new indications of Hans Xiang® and fubutoxin® have been included in the national medical insurance drug catalogue, reflecting the recognition of the clinical value, patient benefits, and degree of innovation of these products by the National Medical Security Administration, improving drug accessibility, reducing patients' medication burden, and promoting the marketing and sales layout of these products.